Physician profile
John C Callison
NPI 1528115334
$7,704.11
in general payments reported to CMS, 2019-2025
46 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $331 · 2021: $307 · 2022: $4,040 · 2023: $813 · 2024: $545 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,476.54 | 2022 | |
| Glaxosmithkline, LLC. | $726.87 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $456.00 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $353.49 | 2019-2025 | Zerbaxa, Recarbrio, Winrevair |
| United Therapeutics Corporation | $339.48 | 2019-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $280.86 | 2019-2025 | Fasenra, Airsupra, Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.73 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $258.87 | 2021-2025 | Avycaz, Teflaro, Creon |
| Insmed, INC. | $254.47 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $147.92 | 2019-2024 | Yupelri, Tobi Podhaler |
| Grifols USA, LLC | $93.44 | 2022-2025 | Prolastin-C Liquid |
| Allergan, INC. | $75.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $75.08 | 2024-2025 | Dupixent |
| Baxter Healthcare | $71.52 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $68.08 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Callison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.